Alumis Inc is a biopharmaceutical entity in the clinical-stage, dedicated to the identification, acquisition, and fast-tracking of transformative medications tailored for autoimmune diseases. The company utilizes its unique precision data analytics technology, biological understanding, and a group of professionals with extensive knowledge in precision medicine drug invention, development, and immunology. This helps Alumis to create treatments that greatly enhance patient's lives by substituting widespread immunosuppression with therapies that are specifically targeted.
Foresite Capital.